3rd TGF-β for Immuno-Oncology Drug Development Summit

Exploit Understanding of TGF-β Biology, Harness Clinically Validated Biomarkers & Advance Safe & Efficacious Clinical Programs for Maximal Therapeutics Benefit in Immuno-Oncology.

In the past year alone, the field has learnt valuable lessons from the clinical trials and from the wider TGF-β field that will equip the immuno-oncology field with the knowledge needed to supercharge future TGF-β monotherapy or combinational therapeutics for precision medicine.

From uncovering the effects and production of TGF-β in immune, tumor and stromal cells to exploring predictive and pharmacodynamic TGF-β biomarkers for patient identification and assessing the clinical challenges that led to recent clinical failures, the 3rd TGF-β for Immuno-Oncology Drug Development Summit is your one-stop-shop dedicated to harnessing you with the knowledge to unlock the potential of successfully targeting TGF-β.

Tailored with 18+ senior leaders, the 2023 meeting will be taking place in-person for the first time - don't miss your chance to be in the room for your comprehensive guide on TGF-β in immuno-oncology!

Whether you are new to this field or a seasoned expert, this meeting will provide you with the must-know takeaways from the basic biology to biomarkers to clinical trial design to overcome the clinical setbacks and produce a blockbuster TGF-β therapeutic.

Prices:
Conference + 2 Workshops - Drug Developer Pricing USD 3297.00
Conference + 1 Workshop - Drug Developer Pricing USD 2848.00
Conference Only - Drug Developer Pricing USD 2399.00
Conference + 2 Workshops - Academic Pricing USD 2797.00
Conference + 1 Workshop - Academic Pricing USD 2448.00
Conference Only - Academic Pricing USD 2099.00
Conference + 2 Workshops - Service Provider Pricing USD 4097.00
Conference + 1 Workshop - Service Provider Pricing USD 3548.00
Conference Only - Service Provider Pricing USD 2999.00

Speakers: Shannon Turley Vice President, Cancer Immunology, Genentech, Marc Pelletier Translational Immuno-Oncology, Novartis, Si Tuen Lee-Hoeflich Director, Translational Sciences, Scholar Rock, Assieh Saadatpour, Associate Director, Johnson & Johnson, Aysha Saeed, Lead Research Analyst, Beacon, Dori Thomas-Karyat, Chief Executive Officer, Synthis, Jian Chen, Director Translational Research & Preclinical Development BioAtla, Kamal Dua, Senior Lecturer, Pharmacy University of Technology Sydney, Kristina Young, Medical Director & Radiation Oncologist, The Oregon Clinic, Lu Gan VP, Head of Medical Research/Oncology, Scholar Rock, Mary Helen Barcellos-Hoff Professor, University of California, San Francisco, Michael Lahn, Chief Medical Officer, iOnctura, Mustafa Khasraw, Professor & Medical Oncologist, Duke University, Natalia Blanco, Principal Scientist, Morphic Therapeutics, Rachael Brake, Chief Scientific Officer, Corbus, Ryan Eberwine, Senior Scientist, Johnson & Johnson, Scott Turner, Senior Vice President & Head of Research, Pliant Therapeutics, Stephen Nishimura, Professor & Chief of Pathology, University of California San Francisco, Tony Reid, Chief Executive & Scientific Officer

Others Details

Brochure https://go.evvnt.com/1374936-3?pid=6581